VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

30 янв 2023 05:00:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

25 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

03 янв 2023 15:01:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

20 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Investor Conferences

22 ноя 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

17 ноя 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

09 ноя 2022 06:30:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

05 ноя 2022 15:50:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

17 окт 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in September 2022

07 сен 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

10 авг 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

04 авг 2022 06:30:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

06 июл 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

04 июн 2022 13:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

02 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

20 май 2022 15:05:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

16 май 2022 06:30:00 Источник Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in May 2022

05 май 2022 15:05:01 Источник Nasdaq GlobeNewswire

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

03 май 2022 15:33:34 Источник Nasdaq GlobeNewswire

Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022

02 май 2022 18:06:09 Источник Nasdaq GlobeNewswire